Cargando…
The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
BACKGROUND: The discrepant concordance between biopsy and radical prostatectomy (RP) specimen are well reported. To validate the clinical usefulness of neutrophil-lymphocyte ratio (NLR) in discriminating real GS ≥ 7 PCa from biopsy-based GS ≤ 6 PCa in comparison with serum total prostate-specific an...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586011/ https://www.ncbi.nlm.nih.gov/pubmed/28874127 http://dx.doi.org/10.1186/s12885-017-3614-9 |
_version_ | 1783261737276932096 |
---|---|
author | Wang, Hanfeng Gu, Liangyou Wu, Yongjie Feng, Dan Duan, Junyao Wang, Xiaocong Huang, Yong Wu, Shengpan Chen, Jianwen Luo, Guangda Zhang, Xu |
author_facet | Wang, Hanfeng Gu, Liangyou Wu, Yongjie Feng, Dan Duan, Junyao Wang, Xiaocong Huang, Yong Wu, Shengpan Chen, Jianwen Luo, Guangda Zhang, Xu |
author_sort | Wang, Hanfeng |
collection | PubMed |
description | BACKGROUND: The discrepant concordance between biopsy and radical prostatectomy (RP) specimen are well reported. To validate the clinical usefulness of neutrophil-lymphocyte ratio (NLR) in discriminating real GS ≥ 7 PCa from biopsy-based GS ≤ 6 PCa in comparison with serum total prostate-specific antigen (tPSA) and value of their combination. METHODS: One hundred one patients who underwent physical examinations incidentally found elevated tPSA and subsequently received biopsy with a conclusion of GS ≤ 6 and RP with an interval of 4-6 weeks after biopsy were enrolled. NLR and tPSA were obtained within 15 days prior to biopsy. Logistic regression model was applied appropriately; McNemar tests and AUC model were performed to evaluate differences among tPSA, NLR and their combination and corresponding diagnostic power respectively. RESULTS: The pathological results from RP specimen comprised 61 patients with GS ≤ 6 and 100 patients with GS ≥ 7. Higher tPSA and NLR were significantly associated with patients with actual GS ≥ 7 (All P < 0.05) concurrently. Multivariate logistic regression indicated that tPSA (OR = 1.088, 95% C.I. = 1.029-1.151, P = 0.003) and NLR (OR = 1.807, 95% C.I. = 1.021-3.200, P = 0.042) could be independent predictors for GS groupings. Under cutoff value of 14.09 ng/ml for tPSA and 2.25 for NLR, the sensitivity, specificity and accuracy were 60.0%, 80.3% and 67.7% for tPSA, 42%, 88.5% and 59.6% for NLR, and 71.0%, 75.4% and 72.7% for combination of tPSA and NLR (tPSA + NLR) respectively. The sensitivity of tPSA + NLR was significantly higher in comparison with tPSA (P = 0.001) and NLR (P < 0.001). Except for sensitivity, no significant difference was found between tPSA and NLR in specificity (P = 0.227) and accuracy (P = 0.132). tPSA got the largest AUC with 0.732 (p < 0.001, 95% C.I.: 0.651-0.813). CONCLUSIONS: Serum tPSA and NLR were significantly elevated among GS ≥ 7 PCa concurrently. The combination of tPSA and NLR might have additional benefit to biopsy on discriminating real GS ≥ 7 Pca from biopsy-based GS ≤ 6 PCa. More stratification models and prospectively multicenter studies are necessary. |
format | Online Article Text |
id | pubmed-5586011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55860112017-09-06 The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 Wang, Hanfeng Gu, Liangyou Wu, Yongjie Feng, Dan Duan, Junyao Wang, Xiaocong Huang, Yong Wu, Shengpan Chen, Jianwen Luo, Guangda Zhang, Xu BMC Cancer Research Article BACKGROUND: The discrepant concordance between biopsy and radical prostatectomy (RP) specimen are well reported. To validate the clinical usefulness of neutrophil-lymphocyte ratio (NLR) in discriminating real GS ≥ 7 PCa from biopsy-based GS ≤ 6 PCa in comparison with serum total prostate-specific antigen (tPSA) and value of their combination. METHODS: One hundred one patients who underwent physical examinations incidentally found elevated tPSA and subsequently received biopsy with a conclusion of GS ≤ 6 and RP with an interval of 4-6 weeks after biopsy were enrolled. NLR and tPSA were obtained within 15 days prior to biopsy. Logistic regression model was applied appropriately; McNemar tests and AUC model were performed to evaluate differences among tPSA, NLR and their combination and corresponding diagnostic power respectively. RESULTS: The pathological results from RP specimen comprised 61 patients with GS ≤ 6 and 100 patients with GS ≥ 7. Higher tPSA and NLR were significantly associated with patients with actual GS ≥ 7 (All P < 0.05) concurrently. Multivariate logistic regression indicated that tPSA (OR = 1.088, 95% C.I. = 1.029-1.151, P = 0.003) and NLR (OR = 1.807, 95% C.I. = 1.021-3.200, P = 0.042) could be independent predictors for GS groupings. Under cutoff value of 14.09 ng/ml for tPSA and 2.25 for NLR, the sensitivity, specificity and accuracy were 60.0%, 80.3% and 67.7% for tPSA, 42%, 88.5% and 59.6% for NLR, and 71.0%, 75.4% and 72.7% for combination of tPSA and NLR (tPSA + NLR) respectively. The sensitivity of tPSA + NLR was significantly higher in comparison with tPSA (P = 0.001) and NLR (P < 0.001). Except for sensitivity, no significant difference was found between tPSA and NLR in specificity (P = 0.227) and accuracy (P = 0.132). tPSA got the largest AUC with 0.732 (p < 0.001, 95% C.I.: 0.651-0.813). CONCLUSIONS: Serum tPSA and NLR were significantly elevated among GS ≥ 7 PCa concurrently. The combination of tPSA and NLR might have additional benefit to biopsy on discriminating real GS ≥ 7 Pca from biopsy-based GS ≤ 6 PCa. More stratification models and prospectively multicenter studies are necessary. BioMed Central 2017-09-06 /pmc/articles/PMC5586011/ /pubmed/28874127 http://dx.doi.org/10.1186/s12885-017-3614-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wang, Hanfeng Gu, Liangyou Wu, Yongjie Feng, Dan Duan, Junyao Wang, Xiaocong Huang, Yong Wu, Shengpan Chen, Jianwen Luo, Guangda Zhang, Xu The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 |
title | The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 |
title_full | The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 |
title_fullStr | The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 |
title_full_unstemmed | The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 |
title_short | The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 |
title_sort | values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real gleason score ≥ 7 prostate cancer from group of biopsy-based gleason score ≤ 6 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586011/ https://www.ncbi.nlm.nih.gov/pubmed/28874127 http://dx.doi.org/10.1186/s12885-017-3614-9 |
work_keys_str_mv | AT wanghanfeng thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT guliangyou thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT wuyongjie thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT fengdan thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT duanjunyao thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT wangxiaocong thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT huangyong thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT wushengpan thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT chenjianwen thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT luoguangda thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT zhangxu thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT wanghanfeng valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT guliangyou valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT wuyongjie valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT fengdan valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT duanjunyao valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT wangxiaocong valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT huangyong valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT wushengpan valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT chenjianwen valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT luoguangda valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 AT zhangxu valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6 |